Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Urological Cancer Market (Bladder, Kidney, Prostate, And Testicular) Growth Forecast at 10.39% CAGR to 2022

Posted on: 16 Sep 16

PR Newswire

PUNE, India, September 16, 2016

PUNE, India, September 16, 2016 /PRNewswire/ -- adds "Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics" 2016 research report to its store. This research states that a strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence. The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%.

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer - the key indications covered in this report - accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies. Complete report on Global Urological Cancer Market Research with 20 market data tables and 78 figures, spread across 143 pages is available at .

Company Analysis and Positioning discussed in this research are Pfizer, Novartis, Johnson & Johnson, Astellas, AstraZeneca and Bristol-Myers Squibb. Key Marketed Products dicussed in this report are Zytiga (abiraterone acetate), Xtandi (enzalutamide), Sutent (sunitinib malate), Votrient (pazopanib hydrochloride), Inlyta (axitinib), Jevtana (cabazitaxel), Xofigo (radium Ra 223 dichloride), Provenge (sipuleucel-T) and Opdivo (nivolumab) - Bristol-Myers Squibb.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies - such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Order a copy of this report @ .

Scope of this report: The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market. The mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications. The market shares and CAGRs of the top 20 companies compare within this therapy area and What proportion of the key players' revenues will be attributable to urological cancers.

Another newly published market research report titled Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market states that there are currently 1,234 pipeline products in active development in the hematological cancer therapy area, and for each of the three key indications, the composition by stage of development is relatively similar, although leukemia and myeloma have more products in clinical development. Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development. Hematological Cancers market research report of 147 pages is available at .

Explore more reports on Pharmaceuticals.

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
2nd Floor, Metropole,
Next to Inox Theatre, Bund Garden Road,
Pune - 411001.
Maharashtra, India.
+ 1 888 391 5441

Connect With Us on:



Twitter:  https: //

G+ / Google Plus:

RSS/Feeds:  http: //

SOURCE ReportsnReports

PR Newswire

Last updated on: 16/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.